Track topics on Twitter Track topics that are important to you
PARIS, FRANCE / ACCESSWIRE / September 17, 2018 / Pharnext SA (FR0011191287 - ALPHA) a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based o...
Dow Jones received a payment from EQS/DGAP to publish this press release. Pharnext Pharnext to Present at BMO 2018 Prescriptions for Success Healthcare Conference 10-Dec-2018 / 08:54 CET/CEST Diss...
NewsPXT3003 is being evaluated in an international pivotal Phase 3 clinical trial in adults with CMT1A, with top-line results expected by October 2018.
This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 ALPHA), a biopharmaceutical company pion...
Dow Jones received a payment from EQS/DGAP to publish this press release. Pharnext Pharnext Announces the Appointments of Susanne Dorn as Chief Regulatory Officer and Serge Fitoussi as Chief Medic...
Pharnext is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. P...
We have published hundreds of Pharnext SAS news stories on BioPortfolio along with dozens of Pharnext SAS Clinical Trials and PubMed Articles about Pharnext SAS for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharnext SAS Companies in our database. You can also find out about relevant Pharnext SAS Drugs and Medications on this site too.